Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus Pharmaceutical Registers Increased Q1 Growth; Will Pursue Acquisitions, Product Diversification

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Beijing-based Lotus Pharmaceuticals will further diversify its product portfolio and make acquisitions in the long term, the company said at the back of announcing increased growth figures over the first quarter ended March 31

You may also be interested in...



Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec

SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA

Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec

SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA

Lotus Set To Build New Manufacturing Facility, Pharma Park In Inner Mongolia

SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and a distributor of Western medicines, is channeling RMB 180 million ($26.3 million) into establishing a new manufacturing base and pharmaceutical park in Inner Mongolia, according to company executives

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel